INBX
Inhibrx Biosciences, Inc.
99.60$
-0.8%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| – | -18.9% | -42.1% | +165.3% | +442.6% | +4.7% | +93.3% | +5.9% | -41.3% | -19.0% | |
| – | -24.3% | -63.4% | +175.1% | +749.4% | +5.3% | +101.6% | +5.3% | -45.7% | -17.2% | |
| – | -32.7% | -84.4% | +448.7% | +1,014.9% | +2.0% | +108.6% | +1.5% | -45.1% | -18.6% | |
| – | -32.7% | -84.4% | +448.7% | +1,014.9% | +2.0% | +108.6% | +1.5% | -45.1% | -18.6% | |
| – | – | -0.9% | -36.5% | +40.4% | +42.8% | -70.7% | +202.7% | -46.0% | -57.9% | |
| – | – | +131.3% | +38.8% | -4,131.2% | – | – | – | – | – | |
| – | +98.0% | +70.5% | +77.5% | -43.1% | +43.7% | +137.4% | +13.6% | -82.2% | +193.5% | |
| – | +68.9% | +81.4% | +27.1% | +52.6% | -28.5% | +22.8% | +104.2% | -27.7% | -17.0% | |
| – | +21.4% | +14.8% | -21.3% | -67.8% | +11.4% | +11.1% | +10.9% | -22.7% | +45.8% | |
| – | +364.1% | +742.6% | -52.3% | +332.0% | -32.2% | -8.8% | +31.6% | -15.6% | -35.7% | |
| – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | -30.6% | +10.8% | -25.1% | +207.1% | -94.0% | |
| – | – | – | – | – | – | – | – | – | – | |
| – | -21.2% | -5.9% | +35.0% | -30.9% | +50.5% | +5.5% | +17.5% | -69.3% | +7.0% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.